StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note published on Sunday morning. The firm issued a sell rating on the stock.
Several other brokerages have also weighed in on MBRX. Maxim Group cut their price objective on shares of Moleculin Biotech from $45.00 to $20.00 and set a buy rating on the stock in a research report on Tuesday, March 26th. Roth Mkm reaffirmed a buy rating and issued a $40.00 price objective on shares of Moleculin Biotech in a research note on Friday, April 12th.
View Our Latest Analysis on Moleculin Biotech
Moleculin Biotech Stock Performance
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last issued its earnings results on Friday, May 10th. The company reported ($2.02) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $1.57. On average, analysts forecast that Moleculin Biotech will post -8.79 EPS for the current year.
Hedge Funds Weigh In On Moleculin Biotech
A hedge fund recently bought a new stake in Moleculin Biotech stock. Atticus Wealth Management LLC bought a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned 0.17% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Stories
- Five stocks we like better than Moleculin Biotech
- 3 Small Caps With Big Return Potential
- AbbVie Stock: A Perfect Dip for Investors to Buy
- NYSE Stocks Give Investors a Variety of Quality Options
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- When to Sell a Stock for Profit or Loss
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.